Spago Nanomedical AB (FRA:7UX) Growth Rank: 2 (As of Sep. 12, 2026) — 67% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7UX Spago Nanomedical AB FRA:7UX
32 GF Score
Price €0.01
! 4 Warning Signs
View Full Analysis

What is Spago Nanomedical AB Growth Rank?

Spago Nanomedical AB FRA:7UX 32 Growth Rank is 2 as of Sep. 12, 2026, which is 67% below its 10-year median of 6.00. GuruFocus rates FRA:7UX with a GF Score™ of 32/100. The stock has 4 warning signs investors should review.

Spago Nanomedical AB has the Growth Rank of 2.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Spago Nanomedical AB Growth Rank Related Terms

FRA:7UX vs VRTX, REGN, MRNA: Growth Rank Comparison

For the Biotechnology subindustry, Spago Nanomedical AB's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Spago Nanomedical AB Growth Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spago Nanomedical AB's Growth Rank distribution charts can be found below:

* The bar in red indicates where Spago Nanomedical AB's Growth Rank falls into.


FRA:7UX
32GF Score
Spago Nanomedical AB FRA:7UX
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 2 mean?
Spago Nanomedical AB (FRA:7UX) has a Growth Rank of 2 as of Sep. 12, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Spago Nanomedical AB and its competitors. This is 67% below median its historical median of 6.00. Over the past decade, Spago Nanomedical AB's Growth Rank has ranged from 3.00 to 9.00.
Is Spago Nanomedical AB's Growth Rank too high?
Spago Nanomedical AB's current Growth Rank of 2 is 67% below median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 9.00. Overall, Spago Nanomedical AB has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Spago Nanomedical AB's Growth Rank compare to VRTX and REGN?
Spago Nanomedical AB's Growth Rank of 2 can be compared against companies in the Biotechnology industry. Historically, Spago Nanomedical AB's own Growth Rank has ranged from 3.00 to 9.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Biotechnology company?
A good Growth Rank depends on the Biotechnology industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Spago Nanomedical AB and its competitors. Spago Nanomedical AB's current Growth Rank is 2, which is 67% below median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spago Nanomedical AB stock overvalued right now?
Spago Nanomedical AB (FRA:7UX) has a current Growth Rank of 2. The current Growth Rank is 2, which is 67% below median its 10-year median of 6.00. Spago Nanomedical AB's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Spago Nanomedical AB (FRA:7UX), the current Growth Rank is 2 as of Sep. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Spago Nanomedical AB Business Description

Other Exchanges SPAGO:Sweden
Address Scheelevagen 22, Lund, SWE, SE-223 63
Spago Nanomedical AB is a nanomedicine company in the field of cancer diagnosis and treatment. The company's product includes SpagoPix and Tumorad. The SpagoPix product aims to improve cancer diagnosis with magnetic resonance imaging through the previous detection of tumors and metastases. The Tumorad products focus on the development of a completely new form of radionuclide therapy for tumor-selective radiation therapy of cancer. The company's development projects are based on a platform of polymeric materials with various properties for the precise diagnosis and treatment of life-threatening and debilitating diseases.
32GF Score

Get the complete analysis for FRA:7UX

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.01
Price